Table 1.

Features of standard neurotoxic chemotherapies that cause chemotherapy-induced peripheral neuropathy (CIPN).

Type	Drug	Mechanism of CIPN	Cumulative and Dose	Incidence of CIPN	Acute Neuropathy	Chronic Neuropathy	Additional Features
Platinum-Based	Cisplatin Carboplatin Oxaliplatin	Nuclear and mitochondrial DNA damage	Cisplatin >300 mg/m2, Oxalipatin >800 mg/m2 may be needed after the first dose	Cisplatin 49–100%, Carboplatin 13–42%, Oxaliplatin 85–95%	Cold-induced dysesthesias (hand/face), Muscle cramps	Sensory neuropathy/ neuronopathy, ataxia	“Coasting”, cranial nerve involvement: hearing loss, tinnitus, ageusia, Lhermitte’s phenomenon
Taxanes	Docetaxel Paclitaxel Nab-paclitaxel Cabazitaxel Ixabepilone	Stabilization of microtubule polymers	Docetaxel ~400 mg/m2 Paclitaxel ~1000 mg/m2; doses of ≥250 mg/m2 may be needed after the first dose	48.2%	Taste impairment	Sensorimotor neuropathy	Occasionally cranial nerves, mononeuropathies, autonomic features, “coasting”
Vinca alkaloids	Vincristine Vinblastine Vinorelbine Vindesine	Destabilization of microtubule polymers	Vincristine >4 mg/m2 may be needed after the first dose	20%; Vincristine 30–40%	Taste impairment	Sensorimotor neuropathy	Occasionally cranial nerves, mononeuropathies, autonomic features, possible ‘coasting’
Brentuximab vedotin	Brentuximab vedotin	Destabilization of microtubule polymers		36–53%	Demyelinating, sensorimotor neuropathy	Autonomic myokymia	Conjugated antibody
Epothilones	Eribulin	Destabilization of microtubule polymers		25%	NS	Sensorimotor neuropathy	Conjugated antibody
Ado-trastuzumab Emtansine	Ado-trastuzumab Emtansine	Destabilization of microtubule polymers		13% after the first dose	NS	Sensorimotor neuropathy	Conjugated antibody
Proteasome inhibitor	Bortezomib Carfilzomib Ixazomib	Proteasome inhibitor			NS	Small fiber neuropathy, Severe polyradiculoneuropathy	Fewer CIPNs with subcutaneous delivery of bortezomib

Abbreviations: NS, not specified.